One-year access to more than 500 world journals available in the system
http://medilib.ir
- Duration of Time : 365 Day
Price
: 300$
- Special Price
: 100$
Order
Journals package 3months
http://medilib.ir
- Duration of Time : 93 Day
- :
Price
: 100$
- Special Price
: 50$
Order
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study
doi : 10.1016/j.eururo.2024.03.036
Buy The Package and View The Article Online
Re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phase 3 Trial. Lancet Oncol 2023;24:1094–108
doi : 10.1016/j.eururo.2023.10.024
Buy The Package and View The Article Online
Reply to Ping Zhong, Xin Liu, and Limin Liao’s Letter to the Editor re: Michele Gnech, Lisette ’t Hoen, Alexandra Zachou, et al. Update and Summary of the European Association of Urology/European Society of Paediatric Urology Paediatric Guidelines on Vesicoureteral Reflux in Children. Eur Urol. 2024;85:433–42
doi : 10.1016/j.eururo.2024.04.027
Buy The Package and View The Article Online